Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
Christopher M MelénMagali MerrienAgata M WasikGeorgios PanagiotidisOlof BeckKristina SonneviHenna-Riikka JunlénBirger ChristenssonBirgitta SanderBjörn Engelbrekt WahlinPublished in: Leukemia & lymphoma (2022)
This phase II clinical trial investigates a one-time oromucosal dose of tetrahydrocannabinol/cannabidiol (THC/CBD) in 23 patients with indolent leukemic B cell lymphomas. Primary endpoint was a significant reduction in leukemic B cells. Grade 1 - 2 adverse events were seen in 91% of the patients; most common were dry mouth (78%), vertigo (70%), and somnolence (43%). After THC/CBD a significant reduction in leukemic B cells (median, 11%) occurred within two hours ( p = .014), and remained for 6 h without induction of apoptosis or proliferation. Normal B cells and T cells were also reduced. CXCR4 expression increased on leukemic cells and T cells. All effects were gone by 24 h. Our results show that a single dose of THC/CBD affects a wide variety of leukocytes and only transiently reduce malignant cells in blood. Based on this study, THC/CBD shows no therapeutic potential for indolent B cell lymphomas (EudraCT trial no. 2014-005553-39).
Keyphrases
- phase ii
- clinical trial
- cell cycle arrest
- induced apoptosis
- acute myeloid leukemia
- open label
- chronic lymphocytic leukemia
- phase iii
- endoplasmic reticulum stress
- cell death
- signaling pathway
- oxidative stress
- end stage renal disease
- study protocol
- pi k akt
- newly diagnosed
- poor prognosis
- ejection fraction
- randomized controlled trial
- peripheral blood